Alnylam Pharmaceuticals has strong growth potential, particularly with Amvuttra for ATTR-CM. Read why ALNY stock justifies a ...

PrEP use increased between 2013 and 2023, according to study findings published in the Journal of the American Medical Association.

There is a lack of understanding among neurologists on how to balance the risks for and benefits of corticosteroids in ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with ...

Wainzua had been previously approved for use by patients with ATTRv-PN in the United States, under the brand name Wainua.

AstraZeneca and Ionis' drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating ...

Ionis Pharmaceuticals (IONS) announced that Ionis’ and AstraZeneca’s (AZN) Wainzua has been recommended for approval by the ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat ...

AstraZeneca Plc. (AZN.L, AZN) and Ionis' Wainzua (eplontersen) has been recommended for approval by the Committee for Medicinal ...

Pharma titan AstraZeneca has announced that its Wainzua nerve damage treatment has been recommended for approval in the EU.

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...